Search This Blog

Friday, August 23, 2013

GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn’s disease did not meet its primary endpoint | 2013 | Press releases | Media | GlaxoSmithKline

GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn’s disease did not meet its primary endpoint | 2013 | Press releases | Media | GlaxoSmithKline

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.